2 Syrup Exported By Maiden Before Product Permission

Hisar : An investigation into the death of 66 children in the Gambia from the cough syrup of Kundli-based Maiden Pharmaceutical Ltd in Sonepat district has revealed that the company had exported 4 types of medicine to Gambia, two of which were even before permission was granted to manufacture the formulation.

Not only this, a lot of flaws have also been found in making BMR (Batch Manufacturing Record) and many other irregularities have also been found.

Maiden Pharmaceutical Ltd was inspected by a team of Central Drugs Standard Control Organization (CDSCO) drug inspectors Sandeep Kumar, Devendra Pratap Singh and Panipat SDCO Rakesh Dahiya after the matter came to light. These defects were found during inspection.

According to the report, Kofexmalin Baby Cough Syrup and MaGrip n Cold Syrup were exported earlier, while permission to manufacture the same was taken later.

In this case, Panipat’s advocate Yashpal had sent a complaint to PM Modi, accusing Haryana FDA’s state drug controller Manmohan Taneja of changing cough syrup samples by taking a bribe of Rs 5 crore from the owner of the company.

The PMO has forwarded it to the Chief Secretary, Government of Haryana for appropriate action.

FDA’s Deputy State Drug Controller Lalit Kumar Goel called the complainant for investigation, but the complainant did not join the investigation, saying it was futile to conduct an investigation by a junior officer against a senior officer.

Contacted Manmohan Taneja in the matter and sent a text message, but he did not present his stand.

  • Related Posts

    • Pharma
    • February 17, 2025
    • 81 views
    GSK Pharma shares gain 20% following strong Q3FY25 results

    GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

    • Pharma
    • February 17, 2025
    • 73 views
    Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

    Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Wow! What a Change of Heart in Practitioners of Allopathy!

    Wow! What a Change of Heart in Practitioners of Allopathy!

    GSK Pharma shares gain 20% following strong Q3FY25 results

    GSK Pharma shares gain 20% following strong Q3FY25 results

    Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

    Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

    US Tariffs on pharma: What are the potential impact on Indian drugmakers

    US Tariffs on pharma: What are the potential impact on Indian drugmakers

    Twin Health bats a1000 before enters Digital Health NY 100

    Twin Health bats a1000 before enters Digital Health NY 100

    US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

    US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%